Landewé RBM, Sieper J, Mease PJ, et al. Efficacy and Safety of Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Patients with Non-Radiographic Axial Spondyloarthritis. ACR 2017, abstract 1787.
Bimekizumab behaalt als eerste primair eindpunt ASAS40-respons na 12 weken
jun 2018 | Spondyloartritis